­
­
­
­

Inventi Rapid - Novel Excipients

Patent Watch

  • Environmentally sensitive foldable oligomers

    The invention relates to oligomers of cholic acid, cholate derivatives and amino acids called "foldamers" that undergo conformational changes in response to changes in temperature, solvent polarity, small molecules, metal ions, and pH. The foldamers can be used in self-assembling monolayers, or as environmental probes to detect changes in the environment, or as protective agents useful for protecting labile materials from the environment, or as a controlled delivery system for delivering drugs and other useful agents to specific in vivo or in vitro sites.

  • Dispersible bosentan tablet

    The invention relates to dispersible tablets comprising the compound 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2- -yl)-pyrimidin-4-yl]-benzenesulfonamide.

  • Film coating

    A film coating composition suitable for use in coating pharmaceutical formulations comprising a) an acrylic polymer dispersion, e.g. an ethylacrylate/methylmethacrylate copolymer such as Eudragit NE30D, b) a surfactant, c) sodium stearyl fumarate, and d) a water-containing liquid useful for the achievement of controlled release from pharmaceutical formulations such as tablets, pellets, etc.

  • Controlled-release galantamine formulations

    Controlled-release galantamine formulations, including controlled-release particles, pellets, granules, and spheres are described. Controlled-release particles, pellets, granules, and spheres with immediate release top-coat are also described. Method of preparing such formulations and method of treating a variety of disorders are also disclosed.

  • Coated tablet formulation and method

    A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin ##STR00001## or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.

  • Pharmaceutical preparation comprising an active dispersed on a matrix

    The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohols, triglycerides, partial triglycerides and fatty acid esters.

  • Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

    Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.

  • EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF DONEPEZIL

    The present invention relates to an extended release pharmaceutical composition for oral administration comprising donepezil or pharmaceutically acceptable salt thereof and a release-controlling agent. Further, it relates to process for preparation of said compositions.

  • PREPARATION OF RASAGILINE AND SALTS THEREOF

    The present invention relates to processes for the preparation of rasagiline mesylate. Also provided is rasagiline mesylate having 90 volume percent of the particles (D.sub.90) with sizes less than about 6 .mu.m and processes for the preparation thereof.

  • FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF

    The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

  • MUCOADHERENTS COMPOSITIONS AND THEIR USE

    The present invention has as its objective to provide mucoadherent compositions with enhanced properties of bioadhesivity, consistency, stability and vaginal pH regulation. It can also be the carrier of an active principle for the treatment or prophylaxis of disturbances or diseases caused in mucosa, particularly in the vaginal tract, as well as their use.

  • EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF GUANFACINE HYDROCHLORIDE

    The present invention relates to an extended release pharmaceutical tablet composition comprising guanfacine comprising: a core containing guanfacine or a pharmaceutically acceptable salt thereof and one or more of pH-independent rate controlling polymer(s) and other pharmaceutically acceptable excipients; optionally a coating over the core as in (a) wherein, the coating comprises one or more of pH-independent rate controlling polymer(s).

  • FLASHMELT ORAL DOSAGE FORMULATION

    There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.

  • PHARMACEUTICAL COMPOSITION SIMULTANEOUSLY HAVING RAPID-ACTING PROPERTY AND LONG-ACTING PROPERTY

    Disclosed is a pharmaceutical composition simultaneously having a rapid acting property and a long-acting property, comprising a sustained-release part coated with a water-insoluble polymer on the surface, comprising a first active pharmaceutical ingredient, at least one release control base selected from the group consisting of water-insoluble polymer, and water-soluble viscous polymer, and a pharmaceutically acceptable carrier; and, an immediate release part comprising a second active pharmaceutical ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition exhibits independent release properties of the immediate release part and the sustained-release part by coating the surface of the sustained-release part comprising an active pharmaceutical ingredient, a release control base and a pharmaceutically acceptable carrier with a water-insoluble polymer to separate it from the immediate release part, and it may be prepared by a relatively simple process without specification limitation to the contents and the kinds of usable pharmaceutically active ingredients.

  • SURFACE ACTIVE PROTEINS AS EXCIPIENTS IN SOLID PHARMACEUTICAL FORMULATIONS

    The invention relates to a use of surface active hydrophobins for applications in pharmaceutical technology, in particular as excipients for galenic use. Provided is a method for either admixture of hydrophobins to galenic compositions or for treating the surface of pharmaceutical forms with a hydrophobin-containing solution to modify the pharmaceutical properties of the galenic form. In a preferred embodiment of the invention hydrophobins are used to improve the properties of a pharmaceutical composition, e.g. to act as a surfactant or to increase resistance to disintegration of the galenic forms to achieve a retarded drug release. The galenic form to be modified by the use of surface active proteins as excipients can be capsules, tablets, pills, microparticles, vesicles, and suppositories, although further galenic forms are envisioned. The surface active proteins used for the purpose of present invention can either be isolated from their respective natural source or prepared by recombinant techniques and expression in a suitable host.

  • PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS

    The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.

  • NOVEL LOWERED AFFINITY ANTIBODIES AND USES THEREFOR

    The present invention provides novel, rationally designed lowered affinity antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall 3 dimensional antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.

  • NOVEL CTLA4-IG IMMUNOADHESINS

    The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.

  • NOVEL MICROBIOCIDES

    Compounds of formula (I), in which the substituents are as defined in claim 1, are suitable for use as microbiocides. ##STR00001##

  • NOVEL PROSTAGLANDIN E1 DERIVATIVE AND NANOPARTICLE HAVING THE SAME ENCAPSULATED THEREIN

    A PGE1 derivative is provided which has an excellent sustained, slow-release PGE1 action. In addition, a PGE1-derivative-containing nanoparticle produced using this PGE1 derivative is provided, which effectively targets an affected site, has excellent drug slow-release properties, and has reduced side effects. This PGE1-derivative-containing nanoparticle is a nanoparticle containing a prostaglandin E1 derivative represented by the following formula (1) ##STR00001## (wherein n denotes an integer of 1 to 12), obtained by hydrophobicizing the prostaglandin E1 derivative with a metal ion, and reacting the hydrophobicized prostaglandin E1 derivative with poly L-lactic acid or a poly(L-lactic acid/glycolic acid) copolymer and a poly DL- or L-lactic acid-polyethylene glycol block copolymer or a poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer.

  • NOVEL COMPOUND RAMALIN AND USE THEREOF

    The present invention relates to a novel compound having excellent antioxidant activity, isolated from Ramalina terebrata, and more particularly to a novel compound, Ramalin, having excellent antioxidant activity, isolated from the Antarctic lichen Ramalina terebrata, a method for preparing the Ramalin, and a pharmaceutical composition, a functional food and a functional cosmetic composition, which contain the Ramalin as an active ingredient. The Ramalin according to the invention has significantly excellent antioxidant effects compared to commercially available antioxidants, and thus can be widely used in agents for treating oxidation-related diseases, anti-aging functional foods, functional cosmetic products for skin whitening and wrinkle reduction, etc.

  • PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED BENZIMIDAZOLE DERIVATIVES

    Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.

  • FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF

    A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described.

  • CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL EMPLOYING A COATING COMPRISING NEUTRAL VINYL POLYMERS AND EXCIPIENTS

    The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipientsportion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.1 to 30% by weight of a plasticizer whereby the excipients of the excipients portion b) are each calculated on the dry weight of the polymer portion a).

  • 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions

    The invention provides compositions comprising formula 1 steroids, e.g., 16.alpha.-bromo-3.beta.-hydroxy-5.alpha.-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16.alpha.-bromo-3.beta.-hydroxy-5.alpha.-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

  • 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS

    The invention provides compound and salts of Formula I and II, disclosed herein, which includes compounds of Formula A and Formula B: ##STR00001## Such compounds possess useful antimicrobial activity. The variables R.sub.2, R.sub.3, R.sub.5, R.sub.6, R.sub.7, and R.sub.9 shown in Formula A and B are defined herein. Certain compounds of Formula I and Formula II disclosed herein are potent and/or selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in animals.

  • Compositions Comprising Amphotericin B

    The present invention comprises compositions and formulations comprising amphotericin B comprising less than 10% degradants, compositions and formulations comprising amphotericin B with one or more excipients, methods of making amphotericin B compositions and formulations, as well as systems for using amphotericin B compositions and formulations. Also provided are pharmaceutical compositions comprising the formulation, methods of administering the pharmaceutical compositions and methods of treating patients with the pharmaceutical compositions.

  • ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONS

    Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.

  • Terpene Glycosides and Their Combinations as Solubilizing Agents

    Several terpene glycosides (e.g., mogroside V, paenoiflorin, geniposide, rubusoside, rebaudioside A, steviol mono-side and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, celecoxib, clofazimine, digoxin, oleandrin, nifedipine, and amiodarone. The use of the diterpene glycoside rubusoside and monoterpene glycoside paenoiflorin increased solubility in all tested compounds. The terpene glycosides are a naturally occurring class of water solubility-enhancing compounds that are non-toxic and that will be useful as new complexing agents or excipients in the pharmaceutical, agricultural (e.g., solubilizing pesticides), cosmetic and food industries.

  • LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS

    The present invention provides, among other things, stable formulations for small modular immunopharmaceutical (SMIP.TM.) proteins. In some embodiments, the present invention provides a formulation containing a lyophilized mixture of a small modular immunopharmaceutical protein, wherein less than 7% of the lyophilized small modular immunopharmaceutical protein exists in aggregated form. Formulations according to the invention may contain buffering agents, stabilizers, bulking agents, surfactants and/or other excipients. The present invention also provides formulations for lyophilization, reconstitution and methods of use thereof.

  • PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT

    Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

  • PHARMACEUTICAL COMPOSITIONS OF VALSARTAN

    The present invention relates to the stable pharmaceutical composition comprising valsartan or a pharmaceutically acceptable salt thereof with mannitol as a filler and povidone as binder. The present invention also relate to the valsartan or pharmaceutically acceptable salt thereof in combination with hydrochlorothiazide or amlodipine or both; and optionally one or more additional excipients.

  • POWDER FORMULATIONS OF POTASSIUM-BINDING ACTIVE AGENTS

    The present invention is directed to powder formulations of a potassium-binding active agent, a suspending agent, and a glidant; optionally, other excipients can be added to the formulations. These formulations can be in a powder form and are useful to bind potassium in the gastrointestinal tract.

  • Albumin-Free Botulinum Toxin Formulations

    This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.

  • AGGLOMERATE FORMULATIONS USEFUL IN DRY POWDER INHALERS

    Several embodiments of the present invention provide for an agglomerate useful for an agglomerate based dry powder inhaler comprising at least one active pharmaceutical agent, at least one additional functional excipient and at least one excipient, such as a binder. Useful at least one additional functional excipientsinclude but are not limited to magnesium stearate, colloidal silica, silicon dioxide, sucrose stearate, L-leucine and combinations thereof.

  • Pharmaceutical Compositions and Therapeutic Methods Employing a Combination of a Manganese Complex Compound and a Non-Manganese Complex Form of the Compound

    A pharmaceutical composition for treatment of a pathological condition in a patient comprises, as a first component, a manganese complex of Formula I( ), and, as a second component, a non-manganese complex compound of Formula (I), optionally together with one or more physiologically acceptable carriers and/orexcipients, wherein X, R, R, R, and R are as defined herein. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering to said patient the first component and the second component. ##STR00001##

  • ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES

    A modified-release oral pharmaceutical composition in capsules with microspheres contains loratadine, phenylephrine and pharmaceutically acceptableexcipients. The composition has immediate bioavailability, with plasmatic concentration values within the therapeutic window with a uniform, continuous release. A method for the production of the composition and a method for treatment as a nasal decongestant and an antihistamine are included.

  • Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients

    A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.

  • Co-Processed Excipient Compositions

    An oral solid dosage form having improved dissolution profile and a method of producing the same are provided. The present invention particularly provides a co-processed excipient composition and a method of producing the same. More particularly, it relates to a co-processed binary mixture of crosslinked polyvinylpyrrolidone and calcium silicate; wherein the weight ratio of crosslinked polyvinylpyrrolidone and calcium silicate is in the range of 1:1 to 20:1. The binary mixture when combined with a poorly soluble drug enhances its dissolution and extent of release.

  • NANOPOLYMETALIC REDUCING AGENT FILLER

    The present invention provides a nanopolymetallic reducing agent filler comprising 20%-70% iron powder, 10%-30% tourmaline power, 2%-15% copper power, 3%-10% bamboo charcoal powder, 2%-15% kaoline, 2%-15% magnesite powder, 2%-15% pyrolusite powder, and 10%-30% zeolite powder. All percentages described above are by weight. A process of forming the nanopolymetallic reducing agent filler is also provided, including grinding and ball milling raw materials of each component respectively into powder particles of 10 nm-100 .mu.m, which are then mixed uniformly by weight percentage and granulated to form a granular mixture, and sintering the granular mixture at high temperature or cold pressing it into a granular filler.

  • INJECTABLE FILLER FOR PODIATRIC AND ORTHOPEDIC USES

    A podiatric filler composition comprising a pliable biocompatible material and a physiologically acceptable suspending agent. The podiatric filler compositions may be used in methods for treating fat pad atrophy, foot pain, plantar faciitis, metatarsalgia, injury, and rheumatoid arthritis.

  • Lubricant Composition

    A podiatric filler composiA lubricant composition which is suitable as a fluorine oil, fluorine grease, and which is excellent in stabilizability, as well as a lubricant composition which is suitable as a fluorine oil, fluorine grease, and which has excellent rust prevention properties while keeping a heat resistance.tion comprising a pliable biocompatible material and a physiologically acceptable suspending agent. The podiatric filler compositions may be used in methods for treating fat pad atrophy, foot pain, plantar faciitis, metatarsalgia, injury, and rheumatoid arthritis.

  • EXCIPIENT COMPATIBILITY WITH EZATIOSTAT

    Disclosed herein is the surprising and unexpected discovery that mannitol inhibits the growth of impurities and enhances shelf life of ezatiostat hydrochloride formulations.

  • Method for Applying a Polymer Coating to an Internal Surface of a Container

    A method of cleaning and coating at least one surface of a container for storing a medicament or other ingestible non-pharmaceutical product, the method comprising the steps of using a water-based cleaning composition in conjunction with a water-based crosslinked acrylic resin containing coating material. The process makes the cleaning and coating technology consistent with present environmental regulations and workplace safety requirements, including control of emissions of volatile organic compounds (VOCs). Further, the concentration of extractible organic compounds has been reduced to the lowest practical level. The process is also applicable to other substrates where it is desired to have low-extractable organics and high adhesion of the subsequently applied coating.

  • COATING COMPOSITIONS, METHODS AND COATED DEVICES

    In various embodiments, a coated device comprises: a substrate; a film coating at least part of the substrate, which film comprises a multilayer unit comprising a first layer and a second layer associated with one another via a hydrogen bond, wherein the first layer comprises a first natural polymeric material and a hydrogen bond donor and wherein the second layer comprises a second natural polymeric material and a hydrogen bond acceptor; and an agent for delivery associated with the coated device. In various embodiments, a coated device comprises: a substrate; a film coating at least part of the substrate, which film comprises a multilayer unit comprising a tetralayer with alternating layers of opposite charge; and an agent for delivery associated with the coated device.

  • SOLUBLE COATING COMPRISING POLYELECTROLYTE WITH HYDROPHOBIC COUNTERIONS

    The present invention provides an implantable device having a biosoluble coating comprising a polyelectrolyte and a counterion and the methods of making and using the same.

  • Polymer Particles and Coating Compositions Formulated from the Polymer Particles

    The invention provides polymer particles useful in a variety of applications, including coating applications such as packaging coatings. The polymer particles preferably have a volume-averaged particle size of less than 40 microns, more preferably less than 20 microns. In preferred embodiments, the polymer particles are precipitated particles, more preferably precipitated polyester particles, which are optionally free of low-molecular weight surfactant.

  • DUAL LANE COATING

    The present invention relates to methods and apparatuses for forming an active-containing film product, while significantly reducing the amount of wasted active material. The resulting product is an active-containing film product that meets the user's predetermined criteria of physical properties and is suitable for use.

  • Coating Comprising An Elastin-Based Copolymer

    A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided. The copolymer may be used as a coating on a stent. Methods of using a stent coated with the copolymer are also provided.

  • Pharmaceutical Compositions Comprising Colloidal Silicon Dioxide

    A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.

  • ORALLY DISPERSIBLE TABLET

    The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture.

  • Fast disintegrating coffee, tea and food powder

    A Super Fast Disintegration Powder that's comprised of tea, coffee and various food extracts, sugars, flavorings, colorants, and a superfast disintigrant. The powder has a particle size of 200 micrometers to 2 mm. The Super Fast Disintegration Powder is comprised of approved and generally recognized as safe sugars, flavorings, FD&C approved coloring agents, vitamins, minerals, nutraceuticals, spices, tea and coffee extracts or any combination thereof, and a Super fast disintegrant that is used as a carrier to deliver the contents. The above ingredients have been heated, sprayed, spun and dried on to a Super Fast Disintegrant for the purpose of establishing a new mode of delivery for tea, coffee and food based products.

  • RAPIDLY DISINTEGRATING SOLID PREPARATION

    Provided is a solid preparation which rapidly disintegrates in the presence of saliva or a small amount of water in the oral cavity, particularly, a rapidly disintegrating solid preparation useful as an orally-disintegrating solid preparation. Specifically provided is a rapidly disintegrating solid preparation containing coated granules wherein saccharide or sugar alcohol having an average particle size of not less than 75 .mu.m and a high dissolution rate is coated with cellulose, and a rapidly disintegrating solid preparation containing a) an active ingredient, b) saccharide or sugar alcohol having an average particle size of not less than 400 .mu.m, c) cellulose and d) adisintegrant.

  • CELLULOSIC GEL MATERIAL AS A PHARMACEUTICAL EXCIPIENT

    A method of making a pharmaceutical tablet comprises (a) combining (i) an aqueous networked cellulose gel with (ii) filler and (iii) an active agent to form a mixture thereof; (b) casting the mixture to form a wet tablet; (c) drying the wet tablet to form a dry pharmaceutical tablet; and then (d) optionally coating the tablet (e.g., with an enteric coating). Pharmaceutical tablets produced by such methods are also described.

  • ORAL ANTIDEPRESSANT FORMULATION WITH REDUCED EXCIPIENT LOAD

    Provided are methods for reducing the excipient load of pharmaceutical formulations containing 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide as the active pharmaceutical ingredient, and compositions related thereto. In particular, provided is a pharmaceutical product comprising 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide and a stabilizer admixed throughout a solid-form unilamellar matrix, wherein the ratio of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide to stabilizer ranges from about 2:3 to about 1:10, and related methods of forming the pharmaceutical product.

  • EXCIPIENT FROM TRIGONELLA FOENUM-GRACEUM SEEDS AND PROCESS FOR PREPARATION THEREOF

    An excipient from Trigonella foenum-graceum seeds and a process for preparation thereof is disclosed. The excipient obtained from Trigonella foenum-graceum seeds, comprising insoluble and soluble dietary fibers can be used in various pharmaceutical or cosmetic compositions and food, nutritional or dietary preparations.

  • SWEETNER COMPOSITIONS WITH REDUCED BITTER OFF TASTE AND METHODS OF PREPARING

    This disclosure pertains to a sweetener composition having reduced bitter off taste. Also disclosed are methods of making a sweetener composition of the present invention and food products using the sweetener composition.

  • EXCIPIENTS FOR NICOTINE-CONTAINING THERAPEUTIC COMPOSITIONS

    A composition intended to be employed for therapeutic purposes incorporates an active ingredient (e.g., a source of nicotine) and at a non-active ingredient that is carried by a porous substrate. The non-active ingredient can be a substance that has the capability of affecting the pH of the biological system to which it is applied (e.g., basic substance and/or buffering agent is sorbed onto the porous carrier, so as to be in intimate contact with that carrier). Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) and nicotine polacrilex. The basic substance can be sodium carbonate, and the porous substrate can be microcrystalline cellulose. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and can be used as a nicotine replacement therapy.

  • CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF

    The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.

  • STABILIZING EXCIPIENT FOR INACTIVATED WHOLE VIRUS VACCINE

    The invention relates to a vaccine composition comprising: a) inactivated whole virus, and b) a stabilizing excipient which comprises: i. a buffer solution, ii. a mixture of essential and nonessential amino acids, iii. a disaccharide, iv. a polyol, v. a chelating agent, vi. urea or a urea derivative, and vii. a nonionic surfactant.

  • Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient

    Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.

  • EXCIPIENT SYSTEM FOR TOPICAL DELIVERY OF PHARMACEUTICAL AGENTS

    The subject invention is based upon the discovery that a wide variety of pharmaceutical agents can be delivered into the skin, fingernails, and toenails of patients by dissolving or dispersing the pharmaceutical agent in a solvent system which is comprised of a combination of an alkyl lactate and Simmondsia chinesis seed oil. The subject invention more specifically discloses a pharmaceutical serum which is comprised of (1) an alkyl lactate, wherein the alkyl group in the alkyl lactate contains from 2 to about 12 carbon atoms, (2) Simmondsia chinesis seed oil, and (3) a pharmaceutical agent. Some representative examples of pharmaceutical agent which can be incorporated into the pharmaceutical serums of this invention include, hormones, growth factors (cytokines), antimicrobials, antibacterials, antibiotics, non-steroidal anti-inflammatory agents, immunodilators, anesthetics, plant extracts, vitamins, corticosteroids, hair growth stimulants, and the like.

  • PESTICIDAL COMPOSITION COMPRISING SULPHUR, ACARICIDE AND AN AGROCHEMICAL EXCIPIENT

    The present invention relates to a pesticidal composition comprising an effective amount of sulphur, an effective amount of at least one acaricide selected from the group consisting of bifenazate, fenpyroximate, fenazaquin, hexythiazox, spirodiclofen, spiromesifen and their salts thereof and at least one agrochemically acceptable excipient.

  • DRUG COATED BALLOON CATHETER AND PHARMACOKINETIC PROFILE

    A drug delivery balloon is provided comprising a balloon having a surface, and a coating disposed on at least a portion of the balloon surface, the coating including an cytostatic therapeutic agent, an excipient, and a plasticizer. In accordance with the present subject matter, at least 30% of the coating transfers from the balloon surface within two minutes after inflation of the balloon. Alternatively, at least 30% of the coating transfers from the balloon surface within one minute after inflation. The coating results in an effective pharmacokinetic profile of an cytostatic therapeutic agent in a vasculature or target tissue.

  • FORMULATION SCREENING METHODS, APPARATUSES FOR PERFORMING SUCH METHODS AND FORMULATIONS FORMED BY SUCH METHODS

    A method of screening for candidate compound-excipient combinations comprises dosing a compound into each receptacle of a collection of receptacles, dosing a first set of excipients and a second set of excipients into the receptacles wherein the dosing creates varying combinations of solutions of a first and second excipients within the receptacles, analyzing each receptacle for the presence of a precipitate, and classifying the receptacles based on the presence of a precipitate.

  • Chewing Gum Comprising Chitosan For Use In Reduction Of The Level Of Free Phosphorus Compounds In The Digestive Juice

    A non-medical use of a combination of a phosphorus compound binding agent and an organic acid in a slow release oral delivery system including at least one delivery vehicle and/or excipient, wherein the phosphorus compound binding agent is chitosan, for reducing the level of free phosphorus compounds in the digestive juice.